Corvus Pharmaceuticals Inc

Gesloten

15.25 2.83

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.77

Max

15.25

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.4M

-14M

EPS

-0.15

Werknemers

37

EBITDA

312K

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+107.49% upside

Dividenden

By Acuity

Volgende Winsten

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-199M

1.1B

Vorige openingsprijs

12.42

Vorige sluitingsprijs

15.25

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 jul 2026, 23:51 UTC

Macro News
Correlated Moves

Bitcoin is higher as the Trump administration advances plans for a Strategic Bitcoin Reserve, with a federal purchase expected by Q4 2026.

4 jul 2026, 23:41 UTC

Canada's Balance of Trade data set for July 7, 2026, forecasts a C$2.4 billion surplus amid cautious market optimism despite geopolitical tensions and U.S.-Canada trade concerns.

4 jul 2026, 23:41 UTC

Brazil's July Inflation Rate Release Sparks Caution Amid Mixed Economic Signals and Global Monetary Policy Shifts

4 jul 2026, 23:41 UTC

Brazil's June 2026 Inflation Rate Release Sparks Cautious Optimism Amid Easing Pressures and Global Economic Influences

4 jul 2026, 23:41 UTC

Mexico's June 2026 Inflation Rate Release on July 9 Expected to Influence Market Sentiment Amid Global Economic Trends.

4 jul 2026, 23:41 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Reflect Resilience Amid Geopolitical Tensions and Market Optimism Following Record Highs

4 jul 2026, 23:41 UTC

Mexico's Inflation Rate MoM Release on July 9 Expected to Reflect Global Economic Pressures Amid U.S. Monetary Policy Concerns.

4 jul 2026, 23:41 UTC

U.S. Imports Data Release on July 7, 2026: Market Anticipates Impact of Tariffs and Global Trade Dynamics Amid Cautious Optimism for Economic Stabilization.

4 jul 2026, 23:41 UTC

U.S. Trade Deficit Expected at $78.8 Billion Amid Weak Job Growth and Easing Geopolitical Tensions

4 jul 2026, 23:32 UTC

Cryptocurrency Market Gains Amid Weak U.S. Job Data and Cautious Fed Outlook

4 jul 2026, 23:32 UTC

Bitcoin and Ethereum rise amid positive market sentiment following disappointing U.S. jobs data and easing geopolitical tensions, while investors anticipate key economic releases next week.

4 jul 2026, 23:32 UTC

U.S. job growth disappoints, shifting Fed rate hike expectations, while Eurozone PMI stabilizes and car registrations surge in Germany.

4 jul 2026, 23:32 UTC

Cryptocurrency market shows recovery as Bitcoin and Ethereum post gains, while U.S. job growth disappoints, reducing Fed rate hike expectations ahead of July FOMC meeting.

4 jul 2026, 23:21 UTC

Macro News
Correlated Moves

Ethereum is advancing today, buoyed by Federal Reserve Chair Kevin Warsh's remarks on easing inflation risks and strong market interest ahead of Pepeto's presale.

4 jul 2026, 23:11 UTC

Correlated Moves

The Russell 2000 Index is trading lower in after-market hours, reflecting a decline since Friday's close amid limited momentum and macroeconomic influences.

4 jul 2026, 23:11 UTC

Correlated Moves

After-market trading for the Dow Jones Index shows a decline, reflecting a cumulative drop since Friday's close amid shared macroeconomic factors with the S&P 500.

4 jul 2026, 23:01 UTC

The FTSE 100 Index is lower in after-hours trading, reversing earlier gains. It remains above its 20-day moving average and near its one-month range.

4 jul 2026, 23:01 UTC

Correlated Moves

Cardano is rising, supported by Ethereum's gains and positive market sentiment. The asset remains above its 20-day moving average, with strong performance over four sessions.

4 jul 2026, 23:01 UTC

Macro News

The S&P 500 Index is lower in after-market hours amid rising memory chip costs and escalating geopolitical tensions following a Ukrainian drone attack.

4 jul 2026, 23:01 UTC

The Nasdaq 100 Index is lower in after-hours trading, continuing a decline since Friday's close without any specific news to explain the movement.

4 jul 2026, 22:51 UTC

Brazil's Retail Sales MoM data set for July 8, 2026, shows cautious optimism as analysts predict recovery from April’s -1.5% decline amid positive economic sentiment linked to World Cup events.

4 jul 2026, 22:51 UTC

The DAX 30 Index is trading lower in after-market hours, reflecting a decline since Friday's close and contrasting with recent upward momentum.

4 jul 2026, 22:41 UTC

Cautious Optimism Grows Ahead of MBA Mortgage Rate Release Amid Easing Inflation and Weaker Jobs Data

4 jul 2026, 22:31 UTC

Japan's Current Account Data Release on July 7, 2026, Forecasts JPY 4.12 Trillion Surplus Amid Market Volatility and Global Economic Concerns.

4 jul 2026, 22:31 UTC

Brazil's Central Bank to Discuss SELIC Rate Amid Mixed Economic Signals and Global Influences on July 6, 2026.

4 jul 2026, 22:11 UTC

UK Housing Market Faces Continued Downward Pressure as RICS House Price Balance Forecasts -0.32% Amid Economic Challenges

4 jul 2026, 21:51 UTC

Japan's Household Spending YoY data set for July 6, 2026, expected to decline amid cautious market sentiment and global economic pressures.

4 jul 2026, 21:51 UTC

Japan's Household Spending Expected to Rise 1.4% in May Amid Mixed Economic Sentiment and Positive Service Sector Growth

4 jul 2026, 21:01 UTC

Macro News

Brent crude prices are lower in after-market hours following a Ukrainian drone attack on an oil terminal in St. Petersburg, intensifying the fuel crisis in Russia.

4 jul 2026, 20:21 UTC

ECB President Lagarde's upcoming speech sparks cautious market sentiment on Eurozone interest rate hikes amid easing inflation pressures.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

107.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD  107.49%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat